In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2

Therapeutic Advances in Urology

Volumn 3, Issue 6, 2011, Pages 243-250

  Rubenstein, Marvin ^a   Hollowell, Courtney M P ^b   Guinan, Patrick ^c  

^a Hektoen Institute for Medical Research   (United States)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

androgen receptor; antisense; bcl 2; p300; prostate cancer; therapy

Indexed keywords

ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; PROTEIN BCL 2; PROTEIN P300;

ARTICLE; CELL STRAIN LNCAP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 82955223351     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287211426155     Document Type: Article

References (23)

1. Bouchai J. Santer F.R. Höschele P.P.S. Tomastikova E. Neuwirt H. Culig Z. (2011) Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer. The Prostate 71: 431–437.
2. Debes J.D. Comuzzi B. Schmidt L.J. Dehm S.M. Culig Z. Tindall D.J. (2005) P300 regulates androgen receptor-independent expression of prostate specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65: 5965–5973.
3. Eder I.E. Culig Z. Ramoner R. Thurnher M. Putz T. Nessler-Menardi C. (2000) Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therapy 7: 997–1007.
4. Heemers H.V. Sebo T.J. Debes J.D. Regan K.M. Raclaw K.A. Murphy L.M. (2007) Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 67: 3422–3430.
5. Huang H. Cheville J.C. Pan Y. Roche P.C. Schmidt L.J. Tindall D.J. (2001) PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of BCL-2 expression. J Biol Chem 276: 38830–38836.
6. Klocker H. Eder I.E. Comuzzi B. Bartsch G. Culig Z. (2007) Androgen receptor function in prostate cancer progression, In: Chung L.W.K. Isaacs W.B. Simons J.W. (eds). Prostate Cancer, Humana Press, p. 94.
7. Mu Z. Hachem P. Pollack A. (2005) Androgen receptor function in prostate cancer progression. Prostate Cancer 65: 331–340.
8. Pandini G. Mineo R. Frasca F. Roberts C.T. Jr Marcelli M. Vigneri R. (2005) Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65: 1849–1857.
9. Rubenstein M. Anderson K.M. Tsui P. Guinan P. (2006) Synthesis of branched antisense oligonucleotides having multiple specificities: Treatment of hormone insensitive prostate cancer. Med Hypoth 67: 1375–1380.
10. Rubenstein M. Dunea G. Guinan P. (1994) Growth factor deprivation therapy utilizing antisense oligonucleotides. Drug News Perspect 7: 517–524.
11. Rubenstein M. Guinan P. (2010a) Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of Bcl-2 in LNCaP cells. In Vivo 24: 489–493.
12. Rubenstein M. Hollowell C.M.P. Guinan P. (2011a) Inhibition of bcl-2 by antisense oligonucleotides is followed by a compensatory suppression of caspase-3 in LNCaP cells. Eur J Clin Med Oncol 3: 1–6.
13. Rubenstein M. Hollowell C.M.P. Guinan P. (2011b) In LNCaP cells enhanced expression of the androgen receptor compensates for bcl-2 suppression by antisense oligonucleotides. Ther Adv Urol 3: 73–79.
14. Rubenstein M. Hollowell C.M.P. Guinan P. (2010b) Increased prostate specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR. Med Oncol 27: 1212–1218.
15. Rubenstein M. Hollowell C.M.P. Guinan P. (2011c) Bax expression remains unchanged following antisense treatment directed against bcl-2. Med Oncol 28: 852–858.
16. Rubenstein M. Hollowell C.M.P. Guinan P. (2011d) Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis: Compensatory changes in non-targeted protein expression. In Vivo, in press.
17. Rubenstein M. Hollowell C.M.P. Guinan P. (2011e) Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR. Med Oncol, in press.
18. Rubenstein M. Hollowell C.M.P. Guinan P. (2011f) Bispecific oligonucleotides may induce interferon in LNCaP cells enhancing surface antigen expression: Effect of intra strand base pair complementarity. In Vivo 25: 61–67.
19. Rubenstein M. Mirochnik Y. Bremer E. George D. Freilich L. Guinan P. (2002) Inhibitory effect of antisense oligonucleotides targeting epidermal growth factor receptor may not be related to changes in mRNA levels in human prostate carcinoma cells. Proc AACR 2002 43: 590a.
20. Rubenstein M. Tsui P. Guinan P. (2010b) Treatment of prostate and breast tumors employing mono- and bispecific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2. Med Oncol 27: 592–599.
21. Seigel R. Ward E. Brawley O. Jemal A. (2011) Cancer Statistics, 2011. CA Cancer J Clin 61: 212–236.
22. Yamanaka K. Miyake H. Zangemeister-Wittke U. Jansen B. Gleave M. (2005) Novel bispecific antisense oligonucleotides inhibiting both bcl-2 and Bcl-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proc AACR 45: (online) abstract.
23. Yip K.W. Mocanu J.D. Au P.Y. Sleep G.T. Busson D. Yeh P. (2005) Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11: 8131–8144.